Article

Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome.

CF Center, Department of Pediatrics, University of Milan, Italy.
Hepatology (Impact Factor: 11.19). 01/2003; 36(6):1374-82. DOI: 10.1053/jhep.2002.37136
Source: PubMed

ABSTRACT Incidence of liver disease (LD) associated with cystic fibrosis (CF) and its clinical characterization still is unsettled. We have assessed prospectively the incidence and risk factors of this complication, and its impact on the clinical course of CF. Between 1980 and 1990, we enrolled 177 CF patients without LD in a systematic clinical, laboratory, ultrasonography screening program of at least a 10-year duration. During a 14-year median follow-up (2,432 patient-years), 48 patients developed LD, with cirrhosis already present in 5. Incidence rate (number of cases per 100 patient-years) was 1.8% (95% confidence interval: 1.3-2.4), with sharp decline after the age of 10 years and higher risk in patients with a history of meconium ileus (incidence rate ratio, 5.5; 2.7-11), male sex (2.5; 1.3-4.9), or severe mutations (2.4; 1.2-4.8) at multivariate analysis. Incidence of cirrhosis was 4.5% (2.3-7.8) during a median period of 5 years from diagnosis of liver disease. Among the 17 cirrhotic patients, 13 developed portal hypertension, 4 developed esophageal varices, 1 developed liver decompensation requiring liver transplantation. Development of LD did not condition different mortality (death rate ratio, 0.4; 0.1-1.5) or higher incidence of other clinically relevant outcomes. In conclusion, LD is a relatively frequent and early complication of CF, whose detection should be focused at the first life decade in patients with history of meconium ileus, male sex, or severe genotype. Although LD does not condition a different clinical course of CF, in some patients it may progress rapidly and require liver transplantation.

0 Bookmarks
 · 
79 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatic involvement is often encountered in gastrointestinal (GI) diseases, in part because of the close anatomic and physiologic relations between the liver and GI tract. Drainage of the mesenteric blood supply to the portal vein permits absorbed and/or translocated nutrients, toxins, bacterial elements, cytokines, and immunocytes to gain hepatic access. Liver problems in digestive disorders may range from nonspecific hepatocellular enzyme elevations to significant pathologic processes that may progress to end-stage liver disease. Hepatobiliary manifestations of primary GI diseases in childhood and adolescence are not uncommon and include several well-described associations, such as sclerosing cholangitis with inflammatory bowel disease. Liver damage may also result from the effects of drugs used to treat GI diseases, for example, the hepatotoxicity of immunomodulatory therapies. This review highlights the important features of the hepatic and biliary abnormalities associated with 3 common pediatric GI conditions: inflammatory bowel disease, celiac disease, and cystic fibrosis.
    Journal of Pediatric Gastroenterology and Nutrition 09/2014; 59(3):288-299. DOI:10.1097/MPG.0000000000000444 · 2.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Watch a video presentation of this articleWatch the interview with the authorAnswer questions and earn CME
    10/2014; 4(4). DOI:10.1002/cld.414
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple organ systems including the gastrointestinal tract, pancreas and hepatobiliary systems are affected by cystic fibrosis (CF). Many of these changes begin early in life and are difficult to study in young CF patients. Recent development of novel CF animal models has provided expanded opportunities in the field to better understand of CF pathogenesis and evaluate traditional to innovative therapeutics. In this review, manifestations of CF disease in gastrointestinal, pancreatic and hepatobiliary systems of humans and animal models will be discussed.
    AJP Gastrointestinal and Liver Physiology 01/2015; 308(6). DOI:10.1152/ajpgi.00146.2014 · 3.65 Impact Factor